This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
REGN vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
REGN vs. TECH: Which Stock Is the Better Value Option?
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Lilly Announces Clinical Study Plans for Coronavirus Disease
by Zacks Equity Research
Lilly (LLY) plans to develop its RA drug, Olumiant, as well as a pipeline candidate as potential treatments for COVID-19. Clinical studies are expected to begin this month.
Gilead Reports Promising Data on Experimental Coronavirus Drug
by Zacks Equity Research
Gilead (GILD) reports encouraging data on investigational antiviral, remdesivir, in patients hospitalized with COVID-19.
Coronavirus Testing, Vaccines & Treatments: What You Should Know
by Neena Mishra
We discuss latest developments in tests, vaccines and therapies for COVID-19.
Alnylam (ALNY) Completes Rolling Submission of Lumasiran NDA
by Zacks Equity Research
Alnylam (ALNY) completes rolling submission of the NDA for lumasiran seeking approval for kidney disease, primary hyperoxaluria type 1. The EMA accepts MAA for lumasiran for the same indication.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $501.51, marking a -0.55% move from the previous day.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
by Sweta Jaiswal, FRM
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Esperion's Cholesterol Drugs Receive Approval in Europe
by Zacks Equity Research
Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.
Gilead Partners Second Genome, Boosts Coronavirus Drug Production
by Zacks Equity Research
Gilead (GILD) collaborates with Second Genome for inflammatory bowel disease treatments. The company also plans to ramp up production of remdesivir for coronavirus treatment.
The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale
Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy
by Kinjel Shah
Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.
Regeneron-Sanofi's Dupixent Data Positive in Atopic Dermatitis
by Zacks Equity Research
Regeneron (REGN) and Sanofi announce positive detailed data on Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis.
Glaxo's Nasal Polyps Study on Nucala Meets Primary Endpoints
by Zacks Equity Research
Glaxo's (GSK) phase III study on Nucala in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) meets co-primary endpoints.
5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check
by Tirthankar Chakraborty
A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -
5 Top S&P 500 Stocks That Rallied Last Week Defying Coronavirus
by Nalak Das
Despite coronovirus upsurge, a handful of S&P 500 stocks rallied last week. Some of them carry a favorable Zacks Rank with strong potential for future growth.
REGN, MAR, CWH, TRWH and MANU as Zacks Bull and Bear of the Day
by Zacks Equity Research
REGN, MAR, CWH, TRWH and MANU as Zacks Bull and Bear of the Day
Seattle Genetics Issue Update on Padcev Label Expansion Study
by Zacks Equity Research
Seattle Genetics (SGEN) may receive an expedited approval pathway for Padcev combo to treat patients with locally advanced/metastatic urothelial cancer in the first-line setting in the United States.
Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection
by Zacks Equity Research
Incyte (INCY) plans to work with the FDA for evaluating Jakafi in patients with COVID-19-associated cytokine storm.
5 Top Momentum Stocks for April Amid Coronavirus-Led Turmoil (Revised)
by Nalak Das
A handful of stocks have withstood the market mayhem in March, some of them are momentum players.
Mesoblast's (MESO) BLA for Ryoncil Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts Mesoblast's (MESO) BLA for Ryoncil (remestemcel-L) under a priority review to treat children with steroid-refractory acute graft versus host disease. A decision is pending on Sep 30.
Bull of the Day: Regeneron Pharmaceuticals, Inc. (REGN)
by Benjamin Rains
Regeneron Pharmaceuticals, Inc. (REGN) shares have surged 30% in 2020 as investors clamor for stocks that appear immune to the coronavirus economic downturn...
The Zacks Analyst Blog Highlights: Regeneron, Netflix, Clorox, NVIDIA and SBA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Netflix, Clorox, NVIDIA and SBA
The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton